⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 30, 2024Open Access

TABLE 2 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

Benjamin Garmezy Mitesh J. Borad Rastilav Bahleda Cesar A. Perez Li‐Tzong Chen Shumei Kato Do‐Youn Oh Paul Severson Betty Y. Tam Cheng S. Quah James J. Harding

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

TEAEs by system organ class and grade

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Garmezy et al. (2024) studied this question.

synapsesocial.com/papers/68e6cd14b6db64358764b1dc https://doi.org/10.1158/2767-9764.25723466

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1TABLE 2 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors2024
2TABLE 1 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors2024
3FIGURE 1 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors2024
4Supplementary Methods from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors2024
5Supplementary Methods from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors2024

More related papers

FIGURE 3 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors2024
Supplementary Figure 2 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors2024
Supplementary Figure 2 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors2024